Table 2.

Summary of peptides showing SARS-CoV-2 entry inhibition

Name	Description	Sequence	Target	Inhibitory activity (IC50)	Clinical status	Ref
SBP1	A peptide derived from ACE-PD α1 helix	IEEQAKTFLDKFNHEAEDLFYQS	RBD	–	Preclinical	280
AHB1	Derived from ACE2 Deep sequencing identified three ACE2 helix scaffolded designs	DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVRELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK	RBD	LV: IC50 = 35 nM	Preclinical	281
AHB2	A truncate of AHB2	ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK	RBD	LV: IC50 = 15.5 nM	Preclinical	281
LCB1	De novo interface designs	DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER	RBD	LV: IC50 = 23.54 pM	Preclinical	281
LCB3	De novo interface designs	NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS	RBD	LV: IC50 = 48.1 pM	Preclinical	281
IPB02	A lipopeptide made by adding a cholesterol group to the C-terminal of IBP01	ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK (Chol)	S2-HR1	PsV: IC50 = 0.08 μM	Preclinical	293
EK1	Derived from HR2 (OC43)	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL	S2-HR1	PsV: IC50 = 2.375 μM	Preclinical	289
				LV: IC50 = 2.468 nM
EK1C4	cholesterol group to the C-terminal of EK1	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG-PEG4 (Chol)	S2-HR1	PsV: IC50 = 15.8 nM	Preclinical	289
				LV: IC50 = 36.5 nM
2019-nCoV-HR2P	HR2 (1150–1185)	DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL (aa1168–1203)	S2-HR1	PsV: IC50 = 0.98 μM	Preclinical	200

PsV pseudovirus, LV live virus